Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 14.81.
Forward PE Ratio (14.81) = Close Price ($398.87) / Consensus Forward EPS ($27.15)
FORWARD PE RATIO
14.81
SECTOR MEDIAN · HEALTHCARE
19.76
median of 78 covered companies
CURRENT VS SECTOR MEDIAN
-25.03%
vs the sector median at left
Elevance Health Inc.
Market Cap
$86.50B
Forward PE Ratio
14.81
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Elevance Health Inc. (ELV) | $86.50B | 14.81 |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $83.11B | 14.93 |
| HCA Healthcare, Inc. (HCA)vs › | $91.81B | 13.64 |
| GSK plc (GSK)vs › | $97.77B | 13.54 |
| Cigna Corporation (CI)vs › | $72.86B | 9.04 |
| Sanofi (SNY)vs › | $103.21B | N/A |
| McKesson Corporation (MCK)vs › | $104.80B | 22.79 |
| Boston Scientific Corporation (BSX)vs › | $67.48B | 13.62 |
| Stryker Corporation (SYK)vs › | $106.26B | 18.41 |
| Cencora, Inc. (COR)vs › | $63.28B | 18.16 |
Trailing P/E
17.9
reported TTM EPS
Forward P/E
14.8
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $27.15 implies +20.7% EPS growth vs the reported trailing $22.50.
At today's $398.87 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $27.15 | $25.84 – $28.32 | 14 | 14.7x |
| 2027-12-31 | $29.64 | $29.14 – $30.65 | 14 | 13.5x |
| 2028-12-31 | $34.00 | $32.15 – $36.64 | 4 | 11.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
